reports
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Michiel Declercq
- Thibault Leneeuw
- Wim Lewi
DEME secures two marine works contracts in Italy and Spain
DEME secures two marine works contracts in Italy and Spain DEME’s Dredging & Infra segment has secured two marine works contracts in Southern Europe, highlighting its expertise in environmental remediation and coastal protection. In Italy, DEME will deliver marine works for the prestigious 38th America’s Cup sailing competition in Naples, including offshore breakwaters and seabed remediation at the Bagnoli-Coroglio site. Meanwhile, in Spain, DEME will restore three beaches along the Valencian coastline through a large-scale nourishment project, to combat erosion and safeguard the shoreline ...
DEME haalt twee contracten binnen voor maritieme werken in Italië en S...
DEME haalt twee contracten binnen voor maritieme werken in Italië en Spanje DEME’s Dredging & Infra-segment heeft twee contracten voor maritieme werken binnengehaald in Zuid-Europa, die de expertise op het gebied van milieusanering en kustbescherming in de verf zetten. In Italië zal DEME maritieme werken uitvoeren voor de prestigieuze 38ste America’s Cup-zeilwedstrijd in Napels, waaronder golfbrekers en sanering van de zeebodem op de site Bagnoli-Coroglio. In Spanje zal DEME drie stranden langs de Valenciaanse kustlijn herstellen via een grootschalig ophogingsproject, om erosie tegen te gaa...
Inventiva to Present at the 44th Annual J.P. Morgan Healthcare Confere...
Inventiva to Present at the 44th Annual J.P. Morgan Healthcare Conference Daix (France), New York City (New York, United States), December 17, 2025 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that CEO Andrew Obenshain has been invited to present a corporate overview, and will engage with Inventiva’s leadership team in investor meetings, at the upcoming 44th Annual J.P. Morgan Healthcare Co...
Inventiva présentera à la 44e conférence annuelle J.P. Morgan Healthca...
Inventiva présentera à la 44e conférence annuelle J.P. Morgan Healthcare Daix (France), New York City (New York, États-Unis), le 17 décembre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd’hui que son Directeur général, Andrew Obenshain, a été invité à présenter une vue d’ensemble de la Société et qu’il participera, aux côtés de l’équipe de direction d’Inventi...
- Guy Sips
- Kristof Samoy
DEME wins contract to help restore water quality in the central Nether...
DEME wins contract to help restore water quality in the central Netherlands DEME has won a contract to implement WFD (Water Framework Directive) measures in Central Netherlands. WFD measures are projects aimed at improving water quality in the Netherlands, which are carried out by Rijkswaterstaat. In collaboration with its partner Beens Dredging B.V. (part of Beens Groep B.V.), DEME will execute Lot D at the locations Eemmeer, Ketelmeer, and Zwarte Meer. These works will start in April 2026 and are expected to be completed by December 2027. Attachment ...
DEME wint contract voor herstel van waterkwaliteit in Midden-Nederland
DEME wint contract voor herstel van waterkwaliteit in Midden-Nederland DEME heeft een contract getekend voor de uitvoering van KRW-maatregelen in Midden-Nederland. KRW-maatregelen (Kaderrichtlijn Water) zijn projecten die gericht zijn op het verbeteren van de waterkwaliteit in Nederland, uitgevoerd door Rijkswaterstaat. In samenwerking met partner Beens Dredging B.V. (onderdeel van Beens Groep B.V.) zal DEME Perceel D uitvoeren op de locaties Eemmeer, Ketelmeer en Zwarte Meer. De werkzaamheden starten in april 2026 en de voltooiing wordt verwacht in december 2027. Bijlage ...
- Dominic Rose
- Naresh Chouhan
Thematic - 2026 Outlook - "5 More Years" (55pgs)
For access to the full note, please contact Naresh Chouhan ( ) With EU Pharma (ex-Novo) now having reached decade high valuations vs EuroStoxx600, we believe the sector has broken out & the sustainability of the growth profile will now generate continued strong performance. Consensus 5yr sales & EPS CAGR’s stand at 4% & 7% for 15x 2026 PE. We show there is upside to this from underestimated pipelines where cons. rarely fully models “monster” drugs & from M&A which we expect to be strong at JPM ...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Mathijs Geerts Danau
- Michiel Declercq
- Wim Hoste
- Wim Lewi
DEME secures foundation and cable installation contracts for BC-Wind o...
DEME secures foundation and cable installation contracts for BC-Wind offshore wind farm in Poland DEME has been awarded three contracts for the installation of monopile foundations, inter-array cables, and the export cable at the BC-Wind offshore wind farm in Poland. These new contracts position DEME as a key contributor to Poland’s renewable energy build-out, supporting the country’s energy transition. Attachment
DEME wint contracten voor funderings- en kabelinstallatie voor BC-Wind...
DEME wint contracten voor funderings- en kabelinstallatie voor BC-Wind offshore windpark in Polen DEME heeft drie contracten gewonnen voor de installatie van monopile funderingen, inter-arraykabels en de exportkabel voor het BC-Wind offshore windpark in Polen. Deze nieuwe contracten positioneren DEME als een belangrijke speler in de uitbouw van hernieuwbare energie in Polen en ondersteunen de energietransitie van het land. Bijlage
- Carole Braudeau
- Carole Braudeau
- ING Helpdesk
- Carole Braudeau
- Carole Braudeau
- ING Helpdesk
- Hilde Van Boxstael
- Mathijs Geerts Danau
- Michiel Declercq
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Mathijs Geerts Danau
UCB Detailed results from Fintepla in CDD strengthen epilepsy franchis...
UCB presented detailed results of the positive phase 3 GEMZ study with Fintepla in CDKL5 deficiency disorder (CDD). The drug showed an estimated 52.7% median reduction in countable motor seizure frequency (CMSF) compared with placebo during a 14 week titration and maintenance period and a favourable safety profile. We view this as highly encouraging in this refractory epilepsy population. Given the infantile onset of CDD, we will be curious to see as of which age, patients could be included in t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.